January 28, 2016 – Trillium Therapeutics has acquired all of the outstanding shares of privately-held Fluorinov Pharma, a FACIT portfolio company.
Read More from Trillium Therapeutics Acquires Fluorinov Pharma
January 28, 2016 – Trillium Therapeutics has acquired all of the outstanding shares of privately-held Fluorinov Pharma, a FACIT portfolio company.
Read More from Trillium Therapeutics Acquires Fluorinov Pharma
December 16, 2015 – FACIT’s investment will support the development of Fusion’s radiopharmaceutical FPX-01 for the treatment of cancer.
December 8, 2015 – FACIT acquires exclusive rights to a portfolio of first-in-class WDR5 inhibitors for the treatment of mixed lineage leukemia.
Read More from FACIT Gains Rights to WDR5 Inhibitors for MLL Leukemia
November 19, 2015 – Triphase is evaluating marizomib in combination with bevacizumab in patients with recurrent glioblastoma.
October 14, 2015 – OICR, UHN, Novera Therapeutics collaborate with Johnson & Johnson Innovation to accelerate the development drug candidates for haematological cancers.
July 10, 2015 – Turnstone Biologics Inc., a FACIT portfolio company, has announced the ongoing enrollment of the Marabex™ clinical trial assessing the safety and immune responses in patients with advanced or metastatic, MAGE-A3-expressing solid tumours.
Read More from Turnstone Biologics Announces Enrollment in Landmark Oncolytic Vaccine Trial
May 26, 2015 – Mr. Beshar’s appointment strengthens Fluorinov’s leadership team, adding financial and pharmaceutical industry expertise as Fluorinov accelerates its clinical development activities.
Read More from Luke M. Beshar Appointed to Fluorinov Pharma Board of Directors
May 4, 2015 – FACIT and its partners are pleased to announce the formation of Turnstone Biologics Inc., a biotechnology company focussed on developing treatments for cancer that harness the patient’s own immune system.
May 4, 2015 – With extensive experience guiding biotech companies in matters including corporate development and clinical strategy, Dr. Garceau’s appointment strengthens Fluorinov’s leadership team and adds significant regulatory expertise as Fluorinov transitions to clinical development.
July 14, 2014 – BDC Capital joined as a new investor and Dion Madsen, Senior Managing Partner at BDC Capital, will join Xagenic’s Board of Directors.
Read More from Xagenic Announces Second Closing of $25.5M Series B Financing